Product Code |
mab0015 |
Clone |
7H2 |
Immunogen |
Ganglioside-OAcGD3 |
Target Specificity |
Reacts with OAcGD3 ganglioside : OAcNeuAc alpha 2-8NeuAc alpha 2-3Gal beta 1-4Glc beta 1-1Cer. |
Name |
Ganglioside-OAcGD3 |
Print datasheet
Product type |
Primary antibodies |
Clonality |
Monoclonal antibody |
Isotype |
IgG3 / Kappa |
Produced in |
Mouse |
Species |
All Species |
Labelling |
None |
Appearance |
Lyophilized powder |
Form |
Cell culture supernatant |
Preservatives |
None |
Recommendations |
Must be reconstituted in distilled water. |
Storage |
Lyophilized powder stable for a minimum of 2 years at -20°C. Store reconstituted antibodies at +4°C. For extended periods store in aliquots at -20°C. Antibodies are guaranteed for 6 month from date of receipt. |
Applications |
ELISA, Thin-layer chromatography |
Working dilutions |
Optimal dilution should be determined by the end user. The following are guidelines only : - ELISA : 1/5 to 1/50 - TLC : 1/5 to 1/20 |
Research areas |
Cancer,Neurology,Signal transduction |
Print datasheet
Cerato E. et al. Variable region gene segments of nine monoclonal antibodies specific todisialogangliosides (GD2, GD3) and their O-acetylated derivatives. Hybridoma (1997), 16(4),307-316.
Thomas C.P. et al. Gangliosides protect human melanoma cells from ionizing radiationinduced clonogenic cell death. Glycoconj. J. (1996), 13(3), 377-384.
Zebda N. et al. Deficiency of ganglioside biosynthesis in metastatic human melanoma cells: relevance of CMP-NeuAc:LacCer alpha 2-3 sialyltransferase (GM3 synthase). FEBS Letters (1995), 362(2), 161-164.
Portoukalian J. et al. Shedding of GD2 ganglioside in patients with retinoblastoma. Int. J.Cancer (1993), 53(6), 948-951.